[go: up one dir, main page]

BG105999A - Treatment of osteoarthritis - Google Patents

Treatment of osteoarthritis

Info

Publication number
BG105999A
BG105999A BG105999A BG10599901A BG105999A BG 105999 A BG105999 A BG 105999A BG 105999 A BG105999 A BG 105999A BG 10599901 A BG10599901 A BG 10599901A BG 105999 A BG105999 A BG 105999A
Authority
BG
Bulgaria
Prior art keywords
osteoarthritis
treatment
chlorphenyl
gout
monohydrate
Prior art date
Application number
BG105999A
Other languages
Bulgarian (bg)
Inventor
Carl Mendel
Timothy SEATON
Steve Weinstein
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of BG105999A publication Critical patent/BG105999A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A compound of formula or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorphenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating osteoarthritis or gout. 20 claims
BG105999A 1999-03-19 2001-10-10 Treatment of osteoarthritis BG105999A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12530099P 1999-03-19 1999-03-19
PCT/US2000/007072 WO2000056306A1 (en) 1999-03-19 2000-03-17 Treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
BG105999A true BG105999A (en) 2002-06-28

Family

ID=22419072

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105999A BG105999A (en) 1999-03-19 2001-10-10 Treatment of osteoarthritis

Country Status (20)

Country Link
EP (1) EP1169027A4 (en)
JP (2) JP2002539248A (en)
KR (1) KR20020038567A (en)
CN (1) CN1352552A (en)
AU (1) AU773490B2 (en)
BG (1) BG105999A (en)
BR (1) BR0009081A (en)
CA (1) CA2366660A1 (en)
CZ (1) CZ20013284A3 (en)
HK (1) HK1044702A1 (en)
HU (1) HUP0200494A2 (en)
IL (1) IL145238A0 (en)
MX (1) MXPA01009461A (en)
NO (1) NO20014477L (en)
NZ (1) NZ514016A (en)
PL (1) PL365463A1 (en)
SK (1) SK13342001A3 (en)
TR (1) TR200102699T2 (en)
WO (1) WO2000056306A1 (en)
ZA (1) ZA200107682B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (en) * 1988-03-31 1997-11-12 科研製薬株式会社 Brain function improver
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine.
AU4542993A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
JP3862295B2 (en) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 Anti-obesity agent
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
AU2764495A (en) * 1994-06-01 1995-12-21 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
MA24500A1 (en) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd CARBOXYLIC ACID SALT DERIVATIVE FROM NAPHTHYRIDINE.

Also Published As

Publication number Publication date
CZ20013284A3 (en) 2002-10-16
NO20014477D0 (en) 2001-09-14
BR0009081A (en) 2003-03-05
EP1169027A4 (en) 2004-10-20
MXPA01009461A (en) 2004-03-19
HK1044702A1 (en) 2002-11-01
HUP0200494A2 (en) 2002-08-28
JP2012051904A (en) 2012-03-15
KR20020038567A (en) 2002-05-23
AU773490B2 (en) 2004-05-27
PL365463A1 (en) 2005-01-10
JP2002539248A (en) 2002-11-19
CN1352552A (en) 2002-06-05
TR200102699T2 (en) 2002-03-21
NO20014477L (en) 2001-11-01
SK13342001A3 (en) 2002-04-04
IL145238A0 (en) 2002-06-30
EP1169027A1 (en) 2002-01-09
WO2000056306A1 (en) 2000-09-28
ZA200107682B (en) 2003-06-18
AU3893200A (en) 2000-10-09
NZ514016A (en) 2001-09-28
CA2366660A1 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
IL145240A0 (en) Method of treating eating disorders
KR970703172A (en) Monoamine, diamine, thiol-containing metal chelators (MONOAMINE, DIAMIDE, THIOL-CONTAINING METAL CHELATING AGENTS)
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MY132094A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
PL350412A1 (en) 2−amino−benzoxazinone derivatives for the treatment of obesity
NO996108L (en) 9 oksinerytromycinderivater
MXPA05009668A (en) Azide free process for preparing 1,2-diamino compounds.
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2000056315A8 (en) Treatment of pain
MXPA04006041A (en) Pyridoquinoxaline antivirals.
PL332423A1 (en) Treatment method
CA2310714A1 (en) Process for preparing neuraminidase inhibitor ro-64-0796
PL326554A1 (en) Derivatives of amine and thiourea and inhibitors of nitrogen oxide synthase
BG105999A (en) Treatment of osteoarthritis
TW200517146A (en) Novel composition
MXPA01009469A (en) Treatment to lower platelet adhesiveness.
MXPA01009468A (en) Treatment of pulmonary hypertension.
BG106000A (en) Treatment of hiatial hernia
MXPA02003516A (en) Polymorphic n [3 [[2 (3,4 dimethoxyphenyl) ethyl] amino] propyl] 4 nitro benzamide hydrochloride.
BG105998A (en) Treatment of certain cancers associated with weight gain
BG105996A (en) Method of treating eating disorders
MXPA01009465A (en) Weight loss after pregnancy.
MXPA01009462A (en) Treatment of gallstones.
ES2062940A1 (en) Gastrokinetic agent, process for its preparation and pharmaceutical compositions containing said agent